key: cord-0712623-hblm4n33
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Parental Willingness to Vaccinate Against COVID‐19
date: 2022-03-03
journal: J Paediatr Child Health
DOI: 10.1111/jpc.15940
sha: fdb71a96e81763cd27e8b894f95f6f9f48ab31eb
doc_id: 712623
cord_uid: hblm4n33

nan

A 5-year-old-boy was treated for 12 months with montelukast, in combination with inhaled corticosteroids, after a life-threatening asthma attack. The parents were counselled prior to commencement regarding the potential for neuropsychiatric symptoms during treatment with montelukast.

A decision was made by the parents to cease the montelukast a year later as the boy had had an event-free year. Five days after ceasing the montelukast, he developed severe agitation and anxiety, obsession with insects 'crawling over him', had nightmares and panic attacks and described auditory hallucinations. He has no prior psychiatric history and had been a well-adjusted social little boy. Over the following 8 weeks, his symptoms gradually improved, although he continued to have nightmares for some months. He required psychology intervention. No other stressors have been identified, nor is there any genetic susceptibility present.

In March 2020, the United States Food and Drug Administration (FDA) strengthened existing warnings by requiring montelukast to have a Boxed Warning about serious mental health side effects. 1 This warning includes the statement 'Most reported cases of neuropsychiatric events occurred during montelukast treatment, but some occurred after discontinuation' and 'in some cases symptoms persisted after stopping montelukast or were reported after discontinuation of therapy'. This followed a highlevel review of neuropsychiatric adverse events reported to the FDA Adverse Event Reporting System including data from January 1998 to January 2018. There were 15 cases of withdrawal neuropsychiatric events, six of which were new onset after withdrawal and nine were continued or recurring. Two additional cases, with limited information preventing robust assessment of causality, were identified between January 2018 and May 2019. 2 This case highlights the need for continued pharmacovigilance of montelukast, including awareness that neuropsychiatric events may occur as a withdrawal event. We would like to share our ideas on the publication 'Parental gender differences in 5 attitudes and willingness to vaccinate against COVID-19. 1 ' Goldman and Ceballo 1 mentioned that 'Unique differences between mothers and fathers …. information for parents about a COVID-19 vaccine for children. 1 ' We agree that parental attitude is an important determinant of success in COVID-19 mass vaccination for children. In the present study, several factors are identified, including gender and age of parent. However, attitudes of parents also depend on the local available information and COVID-19 vaccines. In many settings, the parents might trust one type of vaccine, but not other types. For example, in a recent survey from our setting in tropical Asia, parents usually prefer the new COVID-19 vaccine with reported higher efficacy than inactivated COVID-19 vaccine (https://www.bangkokpost.com/thailand/general/ 2263451/most-parentshold-dim-view-of-online-learning-covidjabs-for-kids-poll). Therefore, willingness to have their children vaccinated might also depend on the type of vaccine. Finally, in a recent real-world report, the vaccination site should be easy to access. A major obstacle for mass vaccination for children is parents' difficulty bringing their children to get the vaccine. 

International COVID-19 parental attitude study (COVIPAS) group. Parental gender differences in attitudes and willingness to vaccinate against COVID-19

A National Cross-Sectional Study from the Republic of Kosovo on Lot Quality Assurance Sampling (LQAS) to evaluate the vaccination status of children between 12 and 24 months of age during 2018 to 2020

Conflict of interest: None declared. Author contributions: RM and VW substantially contributed to study conception and design, acquisition of data, analysis and interpretation of data; drafted the article or revised it critically for important intellectual content; and final approval of the version of the article to be published.